• Announcement
  • Miscellaneous

Job offer – Microfluidics Assistant Engineer

Job tittle 

Microfluidics Assistant Engineer

Job description

OKOMERA is seeking a highly-motivated assistant engineer to work on fluidic R&D projects and to produce our microfluidic chips that are the very core of OKOMERA’s technology and know-how. These chips will besold to our first clients in early 2022. The microfluidics assistant engineer will be responsible for the chip quality control and will actively participate in the optimization of all the related processes. On the R&Dside, her/he will perform the microfluidic experiments required to optimize chip design and fluidic protocols. Therefore, she/he will be largely involved in the R&D discussions. The microfluidics assistant engineer will be working under the direct supervision of the microfluidic engineer. Details of missions will varydepending on the level of expertise of the recruited profile.


  • Bachelor of science or equivalent (Bac+2/+3: BTS/DUT/Licence) in laboratory work
  • Great experimental and practical skills
  • Great organization and great autonomy
  • Great reporting skills
  • Ability to work in English within an international team

Ideal candidates may have

  • 2+ years of industrial experience in R&D projects
  • Skills in microscopy
  • Previous experience in microfabrication or in microfluidics would be a real plus

Contract : CDI

Starting Date : from February 2022

Salary : based on experience

Education Level : Bachelor of Science, License, DUT or BTS

Location : Paris, Brain Institute (ICM), Hôpital Pitié-Salpêtrière


About Okomera and Microfluidics for clinical oncology

OKOMERA is a newly created start-up (2020) spun out from Ecole Polytechnique and Institut Pasteur, whose key mission is to help selecting the best treatment for each cancer patient. OKOMERA is currently codeveloping functional ex vivo assays with our clients, key opinion leaders leading research inprecision cancer medicine.

OKOMERA clients currently use our 3D cell culture microfluidic technology [1] to cultivate primary patient cells from tumor biopsies, and/or cell lines, to assess cell functionalities(drug sensitivity, morphology, migration). OKOMERA’s droplet array technology enables to automate the formation of complex 3D cell cultures (micro-tumors with co-cultures, hydrogels), and to test tens to hundreds of individual conditions on a single chip [2]. OKOMERA prides itself on supplying easy-to-use products (fluidic machine, chips and software) built for non-experts who wish to automate high-throughput 3D sample testing.

OKOMERA was awarded the national iLAB prize from BPI France in 2019, the COMET program from WILCO, iscurrently incubated at Hôpital Pitié Salpêtrière in Paris and recently finalized its initial funding round. We are currently a team of 7, and are actively hiring to grow and deliver our alpha solution to our first clients in early 2022.

Contact info

Raphaël TOMASI – Cofounder & CTO – communications@okomera.com


1- Sart, R. F.-X. Tomasi, G. Amselem, and C. N. Baroud, “Multiscale cytometry and regulation of 3D cellcultures on a chip,” Nat. Commun., vol. 8, p. 469, 2017.

2- F. X. Tomasi, S. Sart, T. Champetier, and C. N. Baroud, “Individual Control and Quantification of 3DSpheroids in a High-Density Microfluidic Droplet Array,” Cell Rep., vol. 31, no. 8, 2020.